NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ovid Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.02 +0.01 (+0.25 %) (As of 12/6/2019 08:08 AM ET) Add Compare Today's Range$3.96Now: $4.02▼$4.1450-Day Range$2.09MA: $2.78▼$4.2652-Week Range$1.53Now: $4.02▼$4.44Volume546,711 shsAverage Volume477,629 shsMarket Capitalization$192.22 millionP/E RatioN/ADividend YieldN/ABeta2.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OVID Previous Symbol CUSIPN/A CIK1636651 Webhttp://www.ovidrx.com/ Phone646-661-7661Debt Debt-to-Equity Ratio0.01 Current Ratio3.78 Quick Ratio3.78Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.57 per share Price / Book2.56Profitability EPS (Most Recent Fiscal Year)($2.11) Net Income$-51,980,000.00 Net MarginsN/A Return on Equity-131.50% Return on Assets-107.46%Miscellaneous Employees55 Outstanding Shares47,816,000Market Cap$192.22 million Next Earnings Date3/5/2020 (Estimated) OptionableNot Optionable Receive OVID News and Ratings via Email Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OVID Rates by TradingView Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions What is Ovid Therapeutics' stock symbol? Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID." How were Ovid Therapeutics' earnings last quarter? Ovid Therapeutics Inc (NASDAQ:OVID) released its earnings results on Friday, November, 8th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.02. View Ovid Therapeutics' Earnings History. When is Ovid Therapeutics' next earnings date? Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Ovid Therapeutics. What price target have analysts set for OVID? 8 equities research analysts have issued 12-month price targets for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $27.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.00 in the next year. This suggests a possible upside of 248.3% from the stock's current price. View Analyst Price Targets for Ovid Therapeutics. What is the consensus analysts' recommendation for Ovid Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ovid Therapeutics. Has Ovid Therapeutics been receiving favorable news coverage? News articles about OVID stock have been trending very positive on Friday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ovid Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Ovid Therapeutics. Are investors shorting Ovid Therapeutics? Ovid Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 424,100 shares, a decline of 35.6% from the October 31st total of 659,000 shares. Based on an average daily volume of 610,800 shares, the short-interest ratio is presently 0.7 days. Approximately 1.8% of the company's shares are short sold. View Ovid Therapeutics' Current Options Chain. Who are some of Ovid Therapeutics' key competitors? Some companies that are related to Ovid Therapeutics include Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA), Kura Oncology (KURA), Omeros (OMER), ANI Pharmaceuticals (ANIP), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Synthorx (THOR), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), TherapeuticsMD (TXMD), Axovant Sciences (AXON) and Phathom Pharmaceuticals (PHAT). What other stocks do shareholders of Ovid Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Zynerba Pharmaceuticals (ZYNE), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Heron Therapeutics (HRTX), Marinus Pharmaceuticals (MRNS), Progenics Pharmaceuticals (PGNX), Verastem (VSTM) and AcelRx Pharmaceuticals (ACRX). Who are Ovid Therapeutics' key executives? Ovid Therapeutics' management team includes the folowing people: Dr. Jeremy Max Levin, Chairman & CEO (Age 66)Dr. Matthew J. During, Founder, Chairman of Scientific Advisory Board & Director (Age 62)Ms. Lora Pike, Sr. Director of Investor Relations & PRMs. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Thomas Michael Perone, Sr. VP, Gen. Counsel & Sec. When did Ovid Therapeutics IPO? (OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers. Who are Ovid Therapeutics' major shareholders? Ovid Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Granite Point Capital Management L.P. (0.90%), Redmile Group LLC (0.26%), Millennium Management LLC (0.21%), Virtu Financial LLC (0.05%) and Commonwealth Equity Services LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Institutional Ownership Trends for Ovid Therapeutics. Which major investors are selling Ovid Therapeutics stock? OVID stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC and Granite Point Capital Management L.P.. View Insider Buying and Selling for Ovid Therapeutics. Which major investors are buying Ovid Therapeutics stock? OVID stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Commonwealth Equity Services LLC. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View Insider Buying and Selling for Ovid Therapeutics. How do I buy shares of Ovid Therapeutics? Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Ovid Therapeutics' stock price today? One share of OVID stock can currently be purchased for approximately $4.02. How big of a company is Ovid Therapeutics? Ovid Therapeutics has a market capitalization of $192.22 million. The company earns $-51,980,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe.View Additional Information About Ovid Therapeutics. What is Ovid Therapeutics' official website? The official website for Ovid Therapeutics is http://www.ovidrx.com/. How can I contact Ovid Therapeutics? Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected] MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 265 (Vote Outperform)Underperform Votes: 215 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of momentum investing?